Autopsy report · NCT02371460

Maternal Omega-3 Supplementation to Reduce Bronchopulmonary Dysplasia

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“Recruitment was prematurely terminated by the DSMB due to concern of harm for future participants based on interim data favoring the placebo group, findings from the N3RO trial, and the very low probability of benefit from DHA supplementation”

The sponsor’s own words in the registry.

Life of this trial

Registered 4 months before it started.
Ran for about 8 years before it stopped.
461 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 3
Sponsor: CHU de Quebec-Universite Laval
Sponsor type: University, hospital or other
Conditions: Bronchopulmonary Dysplasia; Child Development; Neonatal and Perinatal Conditions
Interventions: DHA-rich algal oil; Placebo
Participants: 461
Sites: 16
Countries: Canada

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.